Bull case
Immunic is attractive fundamentally because vidofludimus calcium combines a differentiated dual mechanism—DHODH inhibition and Nurr1 activation—with positive Phase 2 evidence in relapsing and progressive MS, including 6.4 versus 2.4 mean cumulative active MRI lesions at 24 weeks and favorable long-term disability durability at week 144. The market opportunity is also substantial, as management and analysts point to a large, heterogeneous MS population, meaningful unmet need around relapse-associated worsening and progression independent of relapse activity, and an oral profile that could capture patients who prefer non-injectable therapy or switch from current treatments. Supportive safety data across 3,500+ patients, with no major hepatotoxicity or serious infection signal, further strengthens the investment case and underpins the potential for meaningful commercial penetration if Phase 3 ENSURE results are positive by the end of 2026.